Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

医学 肥厚性心肌病 内科学 心脏病学 心室流出道梗阻 射血分数 安慰剂 心室流出道 酒精间隔消融 心力衰竭 梗阻性心肌病 病理 替代医学
作者
Martin S. Maron,Theodore P. Abraham,Caroline Coats,Iacopo Olivotto,Matthew M.Y. Lee,Michael Arad,Nuno Cardim,Changsheng Ma,Lubna Choudhury,Hans‐Dirk Düngen,Pablo García‐Pavía,Albert Hagège,Gregory D. Lewis,Michelle Michels,Artur Oręziak,Anjali Owens,Jacob Tfelt‐Hansen,Josef Veselka,Hugh Watkins,Stephen B. Heitner,Daniel Jacoby,Stuart Kupfer,Fady I. Malik,Lisa Meng,Amy Wohltman,Ahmad Masri
出处
期刊:Journal of Cardiac Failure [Elsevier BV]
卷期号:30: S3-S3
标识
DOI:10.1016/j.cardfail.2023.11.006
摘要

Background Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. Methods SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. Results SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. Conclusion SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM. Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
七友完成签到,获得积分10
刚刚
旺旺旺完成签到,获得积分10
刚刚
鳗鱼纸飞机完成签到,获得积分10
1秒前
1秒前
1秒前
晓柳柳完成签到,获得积分10
1秒前
1秒前
Josh发布了新的文献求助10
2秒前
怡然雁凡完成签到,获得积分10
2秒前
哆啦顺利毕业完成签到 ,获得积分10
3秒前
小杭杭弟完成签到,获得积分10
3秒前
万能图书馆应助DASSEINSUUM采纳,获得10
3秒前
QQWQEQRQ完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
Eternity完成签到,获得积分10
5秒前
果蝇之母发布了新的文献求助10
5秒前
大个应助zzz采纳,获得10
5秒前
6秒前
香蕉觅云应助N2采纳,获得10
7秒前
甘蔗侠发布了新的文献求助10
8秒前
PWG发布了新的文献求助10
8秒前
orixero应助kkk采纳,获得10
8秒前
8秒前
lmgj完成签到,获得积分10
9秒前
9秒前
xcm77完成签到,获得积分10
9秒前
9秒前
10秒前
小熙完成签到 ,获得积分10
10秒前
10秒前
King完成签到,获得积分10
11秒前
atown完成签到,获得积分10
11秒前
可爱的函函应助fengbo采纳,获得10
11秒前
科研通AI2S应助张真狗采纳,获得10
11秒前
11秒前
12秒前
李健的小迷弟应助smile采纳,获得10
12秒前
ROMANTIC完成签到 ,获得积分10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969222
求助须知:如何正确求助?哪些是违规求助? 3514124
关于积分的说明 11171948
捐赠科研通 3249361
什么是DOI,文献DOI怎么找? 1794799
邀请新用户注册赠送积分活动 875431
科研通“疑难数据库(出版商)”最低求助积分说明 804779